Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 440

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 440
---
 milestone payments regarded as reasonably achievable (i.e. all potential milestone payments relating to projects in the development phase, for which the future financial consequences are known or probable and for which there is a sufficiently reliable estimate). This line excludes: • commitments given relating to (i) projects in the research phase, amounting to € 14.4billion as of December 31, 2024 and € 16.8 billion as of December 31, 2023 and (ii) payments contingent upon the attainment of sales targets once a product is commercialized, amounting to € 15.2billion as of December 31, 2024 and € 17.9billion as of December 31, 2023 ); • commitments received amounting to € 13.0billion as of December 31, 2024 ( € 10.0billion as of December 31, 2023 ), mainly comprising research, development and commercialization agreements with partners further to the acquisitions of (i) Ablynx ( € 0.7billion as of December 31, 2024 , versus € 0.9billion as of December 31, 2023 ); (ii) Kymab (€ 0.3billion as of December 31, 2024 , versus € 0.2billion as of December 31, 2023 ) and (iii) Provention Bio (€ 0.4 billion as of December 31, 2024 , versus € 0.3billion as of December 31, 2023 ), plus contingent consideration receivable based on attainment of regulatory and sales milestones for commercialized products under the terms of licenses or rights assignment agreements amounting to € 11.2billion as of December 31, 2024 (€ 8.5billion as of December 31, 2023). The major agreements entered into by Sanofi in 2024 are described below: • On May 10, 2024 , Sanofi entered into a co-exclusive licensing agreement with Novavax. The terms of the agreement include (i) a co-exclusive license to co-commercialize Novavax’s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan, and South Korea, where Novavax has existing partnership agreements); (ii) a sole license to Novavax’s adjuvanted COVID-19